Patient characteristics at transplant and transplantation modalities
| Characteristic . | All patients . | Nivolumab-induced GVHD . | ||||
|---|---|---|---|---|---|---|
| No . | Yes . | |||||
| No. . | % . | No. . | % . | No. . | % . | |
| No. of patients | 20 | 100 | 14 | 65 | 6 | 35 |
| Median age, years (range) | 33 (20-51) | 33 (20-48) | 36 (26-51) | |||
| Sex | ||||||
| Female | 9 | 45 | 7 | 2 | ||
| Male | 11 | 55 | 7 | 4 | ||
| ECOG performance status | ||||||
| ≤1 | 15 | 75 | 11 | 4 | ||
| >1 | 5 | 25 | 3 | 2 | ||
| Median No. of lines of prior therapy (range) | 7 (4-13) | 9 (4-13) | 7 (6-7) | |||
| No. of patients with prior autologous transplantations | 20 | 100 | 14 | 100 | 6 | 100 |
| No. of patients who had prior treatments with brentuximab-vedotin | 20 | 100 | 14 | 100 | 6 | 100 |
| Donor type | ||||||
| HLA-matched related | 11 | 55 | 9 | 64 | 2 | 33 |
| Haploidentical | 1 | 5 | 0 | 0 | 1 | 16 |
| HLA-matched unrelated (10/10) | 4 | 20 | 2 | 14 | 2 | 33 |
| HLA-mismatched unrelated (9/10) | 1 | 5 | 1 | 7 | 0 | 0 |
| Unrelated cord blood | 3 | 15 | 2 | 14 | 1 | 16 |
| ATG as GVHD prophylaxis regimen | ||||||
| No | 9 | 45 | 6 | 43 | 3 | 50 |
| Yes | 11 | 55 | 8 | 57 | 3 | 50 |
| Posttransplant complications | ||||||
| Prior history of GVHD | ||||||
| No GVHD | 7 | 35 | 7 | 50 | 0 | |
| aGVHD | 10 | 50 | 4 | 28 | 6 | 100 |
| cGVHD | 3 | 15 | 3 | 22 | 0 | |
| Median time from allo-HCT to relapse/progression, months (range) | 8.5 (2-59) | 13.5 (2-59) | 7.5 (2-15) | |||
| Median time from allo-HCT to nivolumab initiation, months (range) | 23 (2-111) | 28.5 (7-111) | 7.5 (2-19) | |||
| Characteristic . | All patients . | Nivolumab-induced GVHD . | ||||
|---|---|---|---|---|---|---|
| No . | Yes . | |||||
| No. . | % . | No. . | % . | No. . | % . | |
| No. of patients | 20 | 100 | 14 | 65 | 6 | 35 |
| Median age, years (range) | 33 (20-51) | 33 (20-48) | 36 (26-51) | |||
| Sex | ||||||
| Female | 9 | 45 | 7 | 2 | ||
| Male | 11 | 55 | 7 | 4 | ||
| ECOG performance status | ||||||
| ≤1 | 15 | 75 | 11 | 4 | ||
| >1 | 5 | 25 | 3 | 2 | ||
| Median No. of lines of prior therapy (range) | 7 (4-13) | 9 (4-13) | 7 (6-7) | |||
| No. of patients with prior autologous transplantations | 20 | 100 | 14 | 100 | 6 | 100 |
| No. of patients who had prior treatments with brentuximab-vedotin | 20 | 100 | 14 | 100 | 6 | 100 |
| Donor type | ||||||
| HLA-matched related | 11 | 55 | 9 | 64 | 2 | 33 |
| Haploidentical | 1 | 5 | 0 | 0 | 1 | 16 |
| HLA-matched unrelated (10/10) | 4 | 20 | 2 | 14 | 2 | 33 |
| HLA-mismatched unrelated (9/10) | 1 | 5 | 1 | 7 | 0 | 0 |
| Unrelated cord blood | 3 | 15 | 2 | 14 | 1 | 16 |
| ATG as GVHD prophylaxis regimen | ||||||
| No | 9 | 45 | 6 | 43 | 3 | 50 |
| Yes | 11 | 55 | 8 | 57 | 3 | 50 |
| Posttransplant complications | ||||||
| Prior history of GVHD | ||||||
| No GVHD | 7 | 35 | 7 | 50 | 0 | |
| aGVHD | 10 | 50 | 4 | 28 | 6 | 100 |
| cGVHD | 3 | 15 | 3 | 22 | 0 | |
| Median time from allo-HCT to relapse/progression, months (range) | 8.5 (2-59) | 13.5 (2-59) | 7.5 (2-15) | |||
| Median time from allo-HCT to nivolumab initiation, months (range) | 23 (2-111) | 28.5 (7-111) | 7.5 (2-19) | |||
ATG, antithymocyte globulin; ECOG, Eastern Cooperative Oncology Group.